


CLAIMS

1. A dispersible tablet comprising Compound I of the formula



- or a pharmaceutically acceptable salt thereof present in an amount of from 5% to 40% in weight based on the total weight of the tablet.
2. A dispersible tablet comprising (a) Compound I or a pharmaceutically acceptable salt thereof, and (b) at least one pharmaceutically acceptable excipient suitable for the preparation of tablets, wherein Compound I or a pharmaceutically acceptable salt thereof is present in an amount of from 5% to 40% in weight based on the total weight of the tablet.
3. A dispersible tablet comprising an iron-chelating pharmacologically effective amount of Compound I or a pharmaceutically acceptable salt thereof present in an amount of from 5% to 40% in weight based on the total weight of the tablet.
4. The dispersible tablet according to claim 1, 2 or 3 wherein Compound I is in the free acid form.
5. The dispersible tablet according to any one of claims 1 to 4 wherein Compound I is in a crystalline form.
6. The dispersible tablet according to any one of claims 1 to 5 wherein a lubricant is present in less than 1% in weight based on the total weight of the tablet.
7. The dispersible tablet according to claim 6 wherein the lubricant is present in less than 0.4% in weight based on the total weight of the tablet.

8. The dispersible tablet according to any one of claims 1 to 7 wherein the disintegration time of the tablet is of 5 minutes or less.
9. The dispersible tablet according to any one of claims 1 to 8 wherein the disintegration time of the tablet is of 3 minutes or less.
10. The dispersible tablet according to any one of claims 2 to 9 wherein the pharmaceutically acceptable excipients comprise:
  - (i) at least one filler in a total amount of about 35 to 55 % in weight based on the total weight of the tablet,
  - (ii) at least one disintegrant in a total amount of about 10% to 35% in weight based on the total weight of the tablet
  - (iii) at least one binder in a total amount of about 1.5% to 5% in weight based on the total weight of the tablet,
  - (iv) at least one surfactant in a total amount of about 0.2% to 1% in weight based on the total weight of the tablet,
  - (v) at least one glidant in a total amount of about 0.1% to 0.5% in weight based on the total weight of the tablet, and/or
  - (vi) at least one lubricant in a total amount of less than about 0.4% in weight based on the total weight of the tablet.
11. The dispersible tablet according to any one of claims 6 to 10 wherein the lubricant is magnesium stearate.
12. The dispersible tablet according to anyone of claims 1 to 11 containing Compound I in its free acid form in an amount of about 100 mg to 600 mg .
13. A method of administering to a mammal in need of such a treatment a daily dose of 5 to 40 mg/kg of body weight of Compound I as active ingredient.
14. A process for the preparation of the dispersible tablet according to any one of the preceding claims, which process comprises
  - (i) mixing the Compound I or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient;

- 20 -

- (ii) wet-granulating the mixture obtained in (i);
- (iii) mixing the granulates obtained in (ii) with at least one pharmaceutically acceptable excipient to form a mixture; and
- (iv) spraying the lubricant on the materials contacting surfaces of pressing tools of the tableting machine and compressing the mixture obtained in step (iii) to form a tablet.

15. The process according to claim 14 wherein the lubricant is magnesium stearate.